Who Paid My Doc
Rachel Mayorga
Geriatric Medicine Healdsburg, CA Medical Doctor
NPI 1124078365 CMS profile 278463
421 March Ave Ste D, Healdsburg, CA 95448
General payments
$635
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Rachel Mayorga of Healdsburg, CA is reported in the CMS Open Payments database as having received $635 across 26 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 70th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $89 | 4 | |
| 2023 | General | $18 | 1 | |
| 2021 | General | $40 | 1 | |
| 2020 | General | $40 | 2 | |
| 2019 | General | $448 | 18 |
Beside peers
- Rachel Mayorga
- Geriatric Medicine median
- Middle half of Geriatric Medicine
- National median
In program year 2025, general payments to Rachel Mayorga were reported at $89. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.
Show as a table
| Year | Rachel Mayorga | Geriatric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $448 | $122 | $40–$435 | $163 |
| 2020 | $40 | $98 | $25–$349 | $114 |
| 2021 | $40 | $125 | $34–$441 | $132 |
| 2022 | $0 | $124 | $36–$408 | $149 |
| 2023 | $18 | $121 | $41–$383 | $160 |
| 2024 | $0 | $134 | $41–$435 | $164 |
| 2025 | $89 | $123 | $35–$408 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 100 drugsPart D claims
4,288
Drug cost
$383,851
Branded share of claims
18.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 85 | $88,380 | |
| Eliquis Apixaban | Brand | 62 | $75,182 | |
| Jardiance Empagliflozin | Brand | 26 | $38,624 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 41 | $30,565 | |
| Creon Lipase/Protease/Amylase | Brand | 23 | $20,702 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 19 | $17,153 | |
| Myrbetriq Mirabegron | Brand | 14 | $15,384 | |
| Januvia Sitagliptin Phosphate | Brand | 15 | $11,883 | |
| Mesalamine Dr Mesalamine | Brand | 12 | $4,919 | |
| Valium Diazepam | Brand | 11 | $4,442 |
The 10 drugs with the highest cost, of 100 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 42 billing codesPaid by Medicare
$165,700
Medicare patients
299
Services billed
6,338
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 44% | |
| Osteoporosis | 29% | |
| Ischemic heart disease | 21% | |
| Atrial fibrillation | 19% | |
| Cancer | 17% | |
| Diabetes | 14% | |
| COPD | 14% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, denosumab, 1 mg J0897 | Office | 23 | 2,460 | $49,807 |
| Vaccine for influenza for injection into muscle 90662 | Office | 76 | 76 | $5,214 |
| Pcv20 vaccine im 90677 | Office | 26 | 26 | $1,882 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 11 | 45 | $45 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
26 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Geriatric Medicine in California
Related records
Geriatric Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Geriatric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.